Ki-67: A Prognostic Parameter in Breast Cancer with Prostate Metastatic Patient

Background: Ki-67, a nuclear protein linked to cellular proliferation, is a critical biomarker in breast cancer prognosis. However, its role in breast cancer metastasis to the prostate remains underexplored due to the rarity of this condition. This study investigates the prognostic significance of Ki-67 in breast cancer patients with prostate metastasis.Materials and methods: A retrospective cohort analysis was conducted on 50 breast cancer patients with prostate metastasis, identified from a tertiary care center's cancer registry (2010-2020). Ki-67 expression was assessed via immunohistochemistry and categorized into low (<15%), intermediate (15-30%), and high (>30%) groups. Overall survival (OS) was analyzed using Kaplan-Meier curves and Cox proportional hazards models, adjusting for age, tumor grade, and hormone receptor status.Results: The median OS was 24 months. High Ki-67 levels were significantly associated with poorer OS (12 months) compared to intermediate (24 months) and low (36 months) levels (p<0.001). Multivariate analysis confirmed high Ki-67 as an independent predictor of poor OS (HR 2.5, p=0.002).Conclusion: Ki-67 is a significant prognostic marker in breast cancer patients with prostate metastasis, with high levels indicating worse outcomes. These findings highlight the importance of Ki-67 in guiding prognosis and treatment in this rare metastatic presentation.

Ki-67: A Prognostic Parameter in Breast Cancer with Prostate Metastatic Patient Keywords:

Ki-67 , breast cancer , prostate Metastasis , Prognosis , Overall survival